Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques
about
Design and pre-clinical evaluation of a universal HIV-1 vaccineHIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBECAutologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeysEvolutionary interactions between N-linked glycosylation sites in the HIV-1 envelopeEscape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.Generation of random mutant libraries with multiple primers in a single reactionR5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse modelGenetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressorsA comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression.A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop.Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.Detailed molecular epidemiologic characterization of HIV-1 infection in Bulgaria reveals broad diversity and evolving phylodynamics.Genetic imprint of vaccination on simian/human immunodeficiency virus type 1 transmitted viral genomes in rhesus macaquesSequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodiesHIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans.Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivityepitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals.Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapyEvidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodiesUnique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses.Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responsesMeasuring HIV fusion mediated by envelopes from primary viral isolates.Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection.Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies.Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from IndiaBalancing reversion of cytotoxic T-lymphocyte and neutralizing antibody escape mutations within human immunodeficiency virus type 1 Env upon transmission.The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques.Molecular Features of the V1-V4 Coding Region of Sexually Transmitted Human Immunodeficiency Virus Type 1.Heavily glycosylated, highly fit SIVMne variants continue to diversify and undergo selection after transmission to a new host and they elicit early antibody dependent cellular responses but delayed neutralizing antibody responses.Independent evolution of human immunodeficiency virus type 1 env V1/V2 and V4/V5 hypervariable regions during chronic infection.Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.
P2860
Q21092234-9EC4BE80-5DD7-4BCB-BA28-868A4FC8F3B0Q21559422-4A5CD071-78A8-4990-80E4-015EF4B55842Q28751926-6425A972-1C9F-437C-9A6C-D4E02A176326Q33269794-4949E489-9877-4090-9E4A-BB73040DF13BQ33504599-DF0BD633-9C91-4246-BB81-49B3B1788B67Q33548933-173C98C6-E824-4099-9BD0-A8910A900ECCQ33640144-385C4EF5-8D86-45A8-AA52-3053E3E7DD65Q33676640-889DC348-7D0B-4297-9028-864547E752A6Q33719511-F481EADE-9740-45CB-84D3-1A3214EEDB4EQ33725673-9122AD4E-D1BA-44D3-AD4F-C5DA1ED7DF09Q33980469-4AA63B48-FFF7-4799-9428-8EFA9CDCFB5FQ34463861-527CBD30-664D-4EF6-B5B4-C4352957C41DQ34594513-081C963F-F398-4584-B187-9E7EE62EFF35Q34635398-55B0C9D4-B6B5-439C-87D7-C35E80512431Q34962907-12B18D42-E30B-4082-927C-A301226257E4Q34982715-48D65816-78B5-460D-B2AF-F688DF861A14Q34990575-7D078015-829E-4195-A0FD-F1CB5A89F713Q35101464-00A4C3AA-7066-4D78-8B4E-A10F8963A898Q35192660-0E0B6213-D556-4583-A42D-18111E46B4C9Q35264750-5799FDD2-E76D-447A-AFE7-54EDF71130A9Q35635083-C6B318D3-4CC3-4FE1-B065-6A3E8417A714Q35636394-9F61B401-7554-4CA9-91BF-A28805AD94C2Q35857254-1B97FC67-F23C-45D0-94C4-256CB2DF4E38Q35857683-B57EB668-6986-4B42-A677-26E8FE4B98C0Q36103090-D2F03835-B793-4AA9-8F84-AE7808D30845Q36315745-6E4B5B7A-9426-4156-97F9-B534F481EAA2Q36424574-E52705AA-D421-4729-924F-D4B114062825Q36585516-749351DD-54CB-410E-A491-12A7E7D08B70Q36845710-85A19A4B-B746-408C-9592-0FC3DDEA2BD0Q36994698-282DAE4F-00E8-4546-9930-A33546CC05D3Q37179996-8FEE7BC0-76A2-4B4F-92F1-7ED0E7E3018CQ37333757-EB6EC5BB-D41C-4847-8BC5-C7708CBBA882Q37547702-C3E1E2F9-1E4D-418D-83B6-4D8A0914147BQ40238313-13073828-9E23-46D0-9132-177A843BE033Q41868926-79257E21-9B32-4BE4-BA6A-1376DE29AEB5Q42737939-A0117675-B61B-491A-810A-A005F498F85BQ43215260-CE510CB1-9B7F-432B-85DE-3C23EB81DFD1
P2860
Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Consistent patterns of change ...... ciency virus-infected macaques
@ast
Consistent patterns of change ...... ciency virus-infected macaques
@en
Consistent patterns of change ...... ciency virus-infected macaques
@nl
type
label
Consistent patterns of change ...... ciency virus-infected macaques
@ast
Consistent patterns of change ...... ciency virus-infected macaques
@en
Consistent patterns of change ...... ciency virus-infected macaques
@nl
prefLabel
Consistent patterns of change ...... ciency virus-infected macaques
@ast
Consistent patterns of change ...... ciency virus-infected macaques
@en
Consistent patterns of change ...... ciency virus-infected macaques
@nl
P2860
P50
P1433
P1476
Consistent patterns of change ...... ciency virus-infected macaques
@en
P2093
N A Doria-Rose
P2860
P304
P356
10.1128/JVI.80.2.999-1014.2006
P407
P577
2006-01-01T00:00:00Z